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ABSTRACT
Epileptic disorders like Dravet Syndrome require novel studies to determine the most
ideal treatment. New research linking the endocannabinoid system (ECS) to epileptic disorders is
arising, but there is still much to be discovered about the function and regulatory impact of the
endocannabinoid system and its receptors in epilepsies like Dravet. In this study, knockout
models of larval and adult zebrafish (Danio rerio) were used to investigate the roles of
cannabinoid receptors 1 & 2 in behavior, brain mitochondrial metabolism, and seizure-induced
activity following exposure to THC and CBD. Larval zebrafish which lacked cannabinoid
receptor 1 exhibited increased locomotion compared to the wild-type (5D) line and cannabinoid
receptor 2 null line. Conversely, adult zebrafish which lacked cannabinoid receptor 1 exhibited
decreased locomotion, while adult zebrafish which lacked cannabinoid receptor 2 exhibited
increased time spent in the periphery in the open field test compared to the wild-type line. Adult
males significantly spent more time in the periphery than females and exhibited higher metabolic
rates during specific stages of mitochondrial respiration regardless of line. Larval zebrafish that
were exposed to THC and CBD following seizure induction by pentylenetetrazole (PTZ) were
unaffected by the cannabinoid treatment, displaying no significant response. While we could not
determine the exact mechanism behind the function of cannabinoid receptors in seizure-induced
activity, this study found that cannabinoid receptors 1 & 2 do play a role in the behavior of
zebrafish and are possibly involved in pathways that may link the ECS to epileptic behavior.
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INTRODUCTION
1.1

Epilepsy

Epilepsy is one of the most broadly defined and oldest neurological disorders in the
world, affecting 65 million people worldwide (Epilepsy Foundation, 2019). About 3.4 million
people in the U.S. have epilepsy, with about 470,000 of those being children (Centers for
Disease Control and Prevention, 2021). It is a noncommunicable disease that is characterized by
seizures, which are sudden, abnormal electrical disturbances that occur between brain cells.
There are two major types of seizures that can occur. The first is a generalized seizure, meaning
both sides of the brain are affected. The second is a focal seizure, which affects one area of the
brain. For two out of every three people experiencing epileptic seizures, the cause of epilepsy is
unknown and deemed idiopathic or cryptogenic (CDC, 2021). Many common causes of epilepsy
include stroke, brain tumors, infections, trauma, anoxia, genetic disorders or neurological
disorders.
Because epilepsy is so broadly defined, it can be difficult to find the appropriate
treatment for a specific epilepsy disorder. Anti-epileptic drugs (AEDs) are the most common
treatment (Boon et al., 2021).There are about 20 readily available AEDs, and they can be
selected for a specific case depending on a person’s size, age, comorbidities, sex, childbearing
ability, and adverse effects. In most cases, AED monotherapy can control seizures (National
Institute of Neurological Disorders and Stroke, 2020). Common side effects of AEDs include
dizziness, drowsiness, mental slowing, fatigue and weight gain, but some are more severe, like
depression, allergic reactions, and damage to the liver and bone marrow. Some AEDs can even
cause other drugs to become less effective if taken simultaneously. However, the effectiveness of
current AEDs is not universal because about 30-40% of patients are nonresponsive to these drugs
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(Schmidt, 2011). Novel treatments are needed in order to target epilepsy disorders in a more
effective and less detrimental way.
1.2

Dravet Syndrome
Dravet Syndrome (DS), or Severe Myoclonic Epilepsy in Infancy (SMEI), is a rare,

genetic epileptic disease that is part of a group called developmental epileptic encephalopathies
(DEEs). The devastating condition is often linked to a heterozygous loss-of-function mutation in
the SCN1A (sodium voltage-gated channel alpha subunit 1) gene which causes sodium ion
channels in the brain to malfunction (Strzelczyk & Schubert-Bast, 2020). Sodium channels are
essential to brain cells, and give rise to the neuronal excitability needed for the body to function
properly. This genetic mutation is found in approximately 85% of patients who are diagnosed
with DS (Strzelczyk et al., 2019).
DS onset occurs in infancy, typically within the first year of life. Tonic-clonic or grand
mal seizures tend to occur first along with fever (Epilepsy Foundation, 2019). Following the first
seizure event, more types of seizures may recur, such as myoclonic seizures, atypical absence
seizures, and more. These may be triggered by stress, photosensitivity, and infection. Child
development is usually normal until after age 2, which is when children begin to develop motor
problems, like a crouched gait or unsteady walking, and growth problems. Prognosis of DS is
unfavorable, often resulting in severe neurophysiological impairment and death. DS is associated
with a high risk of premature mortality and sudden unexpected death in epilepsy (SUDEP)
(Strzelczyk & Schubert-Bast, 2020).
Adding to the devastating prognosis of DS is the fact that it is highly drug resistant.
Current treatments, which can be costly, often involve a combination of modestly effective
drugs. Two well-known primary treatments are valproic acid and clobazam (NORD, 2019).

9

However, most patients still do not reach a seizure-free point throughout their lifetime (Wirrell &
Nabbout, 2019). Some developed anti-seizure medications that block sodium channels can even
exacerbate DS symptoms. An ideal drug treatment has not been determined, but new studies that
target altered metabolism in DS reveal new ways to identify anticonvulsants to treat catastrophic
symptoms that may be related to bioenergetics.
1.3

Endocannabinoid System & Epilepsy
Endogenous cannabinoids or endocannabinoids (ECs) are naturally occurring

cannabinoids that are present in the vertebrate central nervous system (CNS). The human body
produces these endocannabinoids as a way to regulate synaptic transitions in the CNS (Lu &
MacKie, 2016). The two most well-known endocannabinoids, N-arachidonoyl-ethanolamine
(AEA) and 2-arachidonoylglycerol (2-AG), are arachidonic acid derivatives. These
endocannabinoids act as lipophilic ligands that directly affect neuronal excitability by interacting
with cannabinoid receptors on the surface of cells throughout the body (Zou & Kumar, 2018).
AEA and 2-AG are known to affect mood, appetite, pain sensation, inflammatory response, and
memory (Chakravarti et al., 2014). Cannabinoid receptor 1 (CB1) and cannabinoid receptor 2
(CB2) are G-protein coupled receptors (GPCRs) that produce cellular responses when directed
by certain signals like neurotransmitters (Rosenbaum et al., 2009). CB1 receptors are expressed
throughout the CNS, while CB2 receptors predominantly play a role in the mediation of the
immune system (Rowley et al., 2017). Endocannabinoids function like neurotransmitters,
binding to these cannabinoid receptors and causing downstream modulations within the cell.
This process is known as the endocannabinoid system (ECS), and it is an important regulator of
neuronal activity. By understanding the ECS, potential therapeutics may be used to target this
pathway and treat various neurological and physiological conditions.
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Because neuronal hyperexcitability is prevalent in epilepsy, the ECS in epilepsy may be a
potential target (Cheung et al., 2019). CB1 receptors have especially become prevalent in studies
about the ECS due to its direct suppressive action on signaling in the CNS, but there is evidence
that CB2 receptors may also be capable of regulating neuronal activity (Rowley et al., 2017).
Cannabinoid receptor agonists for CB1 and CB2 may have the capability of reducing neuronal
hyperexcitability. There are numerous studies utilizing knockout animal models, in which the
gene coding for the CB1 receptor, cnr1, and the gene coding for the CB2 receptor, cnr2, are
altered so that the receptors are not expressed or function correctly. There is significant statistical
evidence that single cnr knockout models have increased susceptibility to seizures induced by
pentylenetetrazole (PTZ), which is a known GABA receptor antagonist and convulsing agent
(Shapiro et al., 2019). There is also evidence that suggests the ECS plays a role in animal models
of DS, because knockout models are more susceptible to DS seizures and compounds that
enhance endocannabinoid signaling may reverse the effects of DS (Anderson et al., 2022).
1.4

Cannabinoids as Therapeutics
Cannabinoids are naturally occurring chemical compounds that have been utilized for

centuries for their medicinal/pharmaceutical efficacy and for recreational purposes (Andre et al.,
2016). Besides endocannabinoids, there are two other types of cannabinoids: phytocannabinoids
and synthetic cannabinoids. Phytocannabinoids are derived directly from the Cannabis sativa
plant. Of the roughly 100 different compounds present in the plant, two of them are commonly
known and used as therapeutics. The first is ∆9‐tetrahydrocannabinol (THC), which is known to
exhibit anti-spasmodic, anti-inflammatory, anti-cancer, and analgesic effects (Andre et al., 2016).
THC also has a psychoactive component. The second is cannabidiol (CBD), and it is a structural
analog of THC. A major difference between THC and CBD is that CBD does not have a
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psychoactive component. There is anecdotal evidence that CBD can be used as an analgesic,
anxiolytic, appetite stimulant, and for the reduction of nausea and vomiting, but more concrete
studies are necessary to investigate the efficacy of treatment. Additionally, THC acts as an
agonist to CB1 and CB2, while CBD acts as an allosteric modulator to these two receptors
(Ahmed et al., 2018).

Figure 1: Structures of CBD and THC
Cannabinoids are currently being used to treat multiple diseases and conditions, such as
glaucoma, cardiovascular disorders, obesity, inflammatory pain, epilepsy, and neurodegenerative
diseases (Chakravarti et al., 2014). For example, THC has been considered for the treatment of
epilepsy. However, experimental trials have produced mixed results. In some animal trials, THC
has anticonvulsant properties, but in others, THC causes pro-convulsant effects (McCoy et al.,
2018). CBD, in the Epidiolex formulation, is currently approved by the Food and Drug
Administration as therapeutic for three types of epilepsy (DS and Lennox Gastaut syndrome and
more recently tuberous sclerosis complex) (FDA, 2020). There is clinical evidence that CBD
exhibits anticonvulsant properties in those affected by treatment-resistant epilepsy (Pamplona et
al., 2018). Further research is ongoing to determine the efficacy, long-term safety and the
molecular mechanisms of action of THC and CBD in the treatment of epilepsy disorders.
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1.5

Glycolysis & Mitochondrial Oxidative Phosphorylation
Glycolysis is the first sequence of reactions that are part of a catabolic pathway present in

many eukaryotic organisms. During glycolysis, one molecule of glucose is converted into two
molecules of pyruvate, and this process generates two molecules of adenosine triphosphate
(ATP) through the aid of reducing agents and enzymes (Teslaa & Teitell, 2014). Pyruvate is a 3carbon metabolic intermediate that may go on to participate in various other energy-producing
processes depending on the presence or absence of oxygen. If oxygen is not present in the
environment, pyruvate is directly converted to lactate, a process that regenerates the production
of nicotinamide adenine dinucleotide (NAD+) for use in glycolysis. If oxygen is present,
pyruvate participates in the tricarboxylic acid (TCA) cycle. When pyruvate enters the TCA cycle
within mitochondria, this cycle produces carbon dioxide (CO2) and generates the reducing agents
NADH and flavin adenine dinucleotide (FADH2). Both of these agents then participate in the
electron transport chain, which results in the oxidation of NADH and FADH 2 and reduction of
molecular oxygen to water. The effective coupling of the spontaneous oxidation of
NADH/FADH2 to the nonspontaneous phosphorylation of ADP results in the net production of
about 34 ATP per glucose molecule. This process is known as mitochondrial oxidative
phosphorylation.
1.5.1

Roles of Metabolic Pathways in Epilepsy
Altered metabolism has been linked to seizure activity, resulting in a pattern of ictal

hypermetabolism and increased glycolysis followed by interictal hypometabolism (Kumar et al.,
2016). Diet control has been explored as a nonpharmacological treatment to combat epileptic
seizures. The ketogenic diet, a low-carb, high-fat diet, is known to effectively treat some
childhood epilepsies, but it is generally the final treatment option for epilepsies that do not
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respond to antiepileptic drugs (Kossoff et al., 2009). Because of the efficacy of the ketogenic
diet, it may be beneficial to explore the role of metabolism in epileptic disorders. The Seahorse
Bioscience extracellular flux analyzer can be used to study metabolism in the laboratory. With
this instrumentation, it is possible to conduct in vitro metabolic studies on glycolysis and
oxidative phosphorylation. Rates of glycolytic flux are given in terms of the extracellular
acidification rate (ECAR), which is determined by the excretion of lactic acid per unit time
(Teslaa & Teitell, 2014). The oxygen consumption rate (OCR) also allows for the determination
of the amount of mitochondrial oxidative phosphorylation happening within cells. When applied
to biological systems, the use of the Seahorse analyzer can reveal changes in glycolytic and
mitochondrial oxidative phosphorylation rates that may be linked to seizure disorders.
1.6

Zebrafish as an Epilepsy Model
Animal models for epilepsy are crucial for the understanding of epileptic mechanisms in

specific disorders and how to treat them. For genetic epilepsies like DS, genetic mutations that
cause disrupted gene function must be studied by generating these mutations in animal models.
The development of new AEDs also relies on preclinical testing in animal models. Rodent
models have been utilized for the study of DS because of genetic and physiologic similarities
with humans and the ability to introduce the Scn1a mutation in their genome (Schutte et al.,
2016). However, there are potential limitations to the rodent model, like high maintenance costs.
Preclinical testing in rodent models also tends to elicit a broad-spectrum suppression against a
range of different seizure types, which does not help to identify and develop more diseasespecific AEDs (Griffin et al., 2016a).
The use of zebrafish as an alternative model for epilepsy studies has grown significantly
over the past decade. Zebrafish models are capable of behavior-based high-throughput assays,
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showing responses to established AEDs like valproate and diazepam (Schutte et al., 2016).
Additionally, zebrafish are genetically similar to humans. The zebrafish genome can be altered
for the study of certain behaviors or phenotypes (Griffin et al., 2016b). The scn1a mutant
zebrafish model is an example of this. De novo mutations of the human SCN1A gene are
causative in DS, and zebrafish possess two orthologues of this gene, scn1laa or scn1lab, that can
be mutated to recapitulate the epileptic seizures seen in humans affected by DS (Sourbron et al.,
2017).
The ECS is also highly conserved between mammals and zebrafish (Krug & Clark,
2015). Zebrafish express cnr1 and cnr2 (which encode for CB1 and CB2) in the brain and
peripheral tissues, and these receptors function as homeostatic regulators of the neurological
system. There is much to be discovered about the role of the ECS in epilepsies like DS, so the
use of the zebrafish model may be beneficial for further studies. Manipulating the zebrafish
genome to obtain cnr1 and cnr2 knockout models could help to determine the role of the ECS in
epileptic activity and acute effects of cannabinoids like THC and CBD on seizure-induced
behaviors (Bailone et al., 2022).
Zebrafish have many other advantages, including physiological homology to humans,
high availability, and short generation time. These advantages give zebrafish the potential to be
an efficient system for studying seizure-induced behavior, metabolic interventions and novel
pharmaceuticals.

1.7

Study Goals & Hypotheses

The main goals of this study were to:
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1.

Evaluate the effects of non-functional cannabinoid receptors on larval and adult
behavior.

2.

Assess differences in basal mitochondrial bioenergetics among wild-type and
cannabinoid receptor 1 and 2 null zebrafish lines.

3.

Determine the roles of cannabinoid receptors 1 and 2 in PTZ-induced seizures.

4.

Determine the efficacy of THC and CBD in reducing PTZ-induced seizures in
cannabinoid receptor 1 and 2 null lines compared to wild-type.

Hypotheses:
1.

Cnr1-/- larvae will experience higher locomotion and higher anxiety than WT (5D)
in the larval strain. Cnr2-/-larvae will not experience changes in behavior. Adult
mutant lines are expected to follow this pattern of behavior.

2.

Cnr1-/- larvae will experience increased OCR compared to 5D. Cnr2-/- larvae will
not experience significant changes in OCR.

3.

In PTZ-treated cnr1-/- larvae, the addition of THC will result in no significant
reduction of seizures and the addition of CBD will result in decreased seizure
activity compared to WT fish.

4.

In PTZ-treated cnr2-/- larvae, the addition of THC & CBD will result in no
significant reduction of seizures compared to WT fish.

METHODS AND MATERIALS
2.1

Zebrafish husbandry
5D, cnr1-/-, and cnr2-/- fish were used in this study. 5D fish, which were used as a wild-

type control, were obtained from Dr. Robyn Tanguay at Oregon State University. Cannabinoid
receptor 1 and 2 mutant lines (cnr1-/- and cnr2-/-) were obtained from Dr. Wolfram Goessling at
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Harvard Medical School in the Genetics Division of Brigham and Women’s Hospital. Adult
mutant lines were genotyped prior to assessing behavior or conducting larval experiments. Fish
were maintained in Aquatic Habitats Zebrafish Flow-through System under the following
conditions: pH 7.5-8, dissolved oxygen 7.2-7.8 mg/L, conductivity 730-770 µS, temperature 2629°C, and light:dark cycle of 14:10. All protocols were in accordance with the Institutional
Animal Care and Use Committee guidelines.
Embryos were collected prior to larval exposures. Adult fish were placed in breeding
tanks overnight, and in the morning the fish were exposed to light. During the light period, eggs
were laid. To collect, eggs were filtered from the tanks and placed into petri dishes. Debris was
removed from each dish and eggs were counted, raised and incubated in sterilized embryo water
(pH 7.4-7.7, 60 ppm (parts per million) Instant Ocean, 0.05% methylene blue) at 28°C. Embryos
were assessed daily for developmental defects.
2.2

Constitutive larval behavioral assay
At 5 days post fertilization (dpf), unexposed fish (n=46-48 per line from 5D, cnr1-/-, and

cnr2-/- lines) were placed in a 96 well plate with 1 larva per well (300 µL zebrafish embryo water
per well) and behavior in a larval photomotor response assay was measured by the Viewpoint
Zebrabox. Movements were recorded in alternating periods of light and dark for 50 minutes (010 min acclimation, 12-20 min dark: 22-30 min light: 32-40 min dark: 42-50 min light). Once
completed, the Viewpoint Zebrabox created an Excel spreadsheet which included total
movement per fish within each of the alternating light cycles. Total distance was summed and
divided by the minutes in each phase to show the differences in movement rates within the
phases.
2.3

Adult behavioral assessment
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Locomotor activity and anxiety-like behavior was studied in adult lines using the open field
test. 5D, cnr1-/-, and cnr2-/- fish (n=12 fish per sex per line) were separated by sex and analyzed
at age 15-18 months post fertilization. Fish were placed individually in a cylindrical arena
(diameter = 30.5 cm) that was filled with 10 L of water and allowed to swim for 5 minutes at 9
Lux lighting (Figure 2). The Noldus EthoVision XT video tracking system was used to track
movements. Differences in exploratory behavior were collected with the EthoVision software,
which tracked velocity, time spent in periphery, and freezing duration.

Figure 2: Cylindrical arena used in the open field test. There were two zones used for
analysis: zone 1 (the outer zone (periphery)) and zone 2 (the inner zone). The total
diameter was 30.5 cm.
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2.4

Seahorse bioenergetics analysis
Adult brain mitochondria from each line was studied using the Cell Mito Stress Test

(Agilent) conducted by the Seahorse XFe96 analyzer. 5D, cnr1-/-, and cnr2-/- adult brains were
extracted from male and female fish and used to generate four biological replicates per sex
consisting of 3-4 brains per biological replicate, and four technical replicates per biological
replicate. Brain tissues were kept on ice and homogenized in Extraction Buffer with BSA
(bovine serum albumin) and 1x protease inhibitors (1.6 mL per homogenizer tube). Protein
samples were centrifuged twice at 700xg for 10 min at 4oC and once at 10,000xg for 15 min at
4oC. The resulting pellet was resuspended in Extraction Buffer without BSA or protease
inhibitors (1 mL). Samples were centrifuged once again at 10,000xg for 15 min at 4oC and
resuspended in Extraction Buffer without BSA or protease inhibitors (50 L). Mitochondrial
protein was then quantified using the Nanodrop 2000 (ThermoFisher Scientific).
Following protein quantification, the oligomycin, carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP), and rotenone/antimycin A substrates for the assay were prepared and
inserted into the XFe96 sensor cartridge plate for the calibration of the instrument. After
calibration, the mitochondria (50 µg protein per replicate) was attached to the plate by
centrifuging at 2000xg for 20 min at 4oC, all wells had a final volume of 180 µL of DMEM
complete (Dulbecco’s Modified Eagle’s Medium with 1 mM pyruvate, 10 mM glucose, and 2
mM glutamine), and the Cell Mito Stress Test was run following manufacturer’s protocol
(Agilent Seahorse XFe96 Cell Mito Stress Test). To assess mitochondrial function, oxygen
consumption rates (OCR) were measured before the addition of metabolic activators/inhibitors
(baseline respiration) and following the addition of oligomycin (1.5 µM final concentration;
complex V (ATP synthase) inhibitor), FCCP (1 µM final concentration; mitochondrial
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uncoupler), and rotenone/antimycin A (0.5 µM final concentration; complex I/III inhibitor) to the
electron transport chain (Figure 3). For each parameter, OCR was measured three times over the
course of an 18-minute cycle (3-minute mixing, 0-minute waiting, 3-minute measuring period).

Figure 3: Metabolic modifiers added to the electron transport chain in mitochondria during the Cell
Mito Stress Test. Oligomycin is added following the basal respiration stage, inhibiting complex V
(ATP synthase). Next, FCCP is added, which uncouples electron transport to ATP production,
destroying the proton gradient and allowing for maximal respiration through uninhibited electron
flow. Lastly, rotenone/antimycin A, which inhibits complex III and I, prevent the electron transport
chain operation, forcing the cell to move to non-mitochondrial respiration if possible. Created with
BioRender.com.

2.5

CBD and THC larval exposures
At 5 dpf, 5D, cnr1-/-, and cnr2-/- larvae (n=24 larvae per treatment) were placed individually

in wells of a 96-well plate. Fish were dosed with 150 µL dosing water: control (0.05% dimethyl
20

sulfoxide, DMSO), diazepam (DZP; 25 µM), CBD (0.6 and 1 µM), or THC (1 and 4 µM). These
CBD and THC concentrations were chosen because they have previously reduced PTZ-induced
total distance moved (Thornton et al., 2020). Plates were covered with aluminum foil and placed
in a 28oC incubator for 24 hours. After the 24-hour exposure, larvae were examined for
deformities and mortality. Larvae with deformities were excluded from behavioral analysis.
2.5.1

Seizure induction
After 24 hours of exposure, seizures were induced by the addition of pentylenetetrazole

(PTZ; 5 mM final concentration) with the exception of the control group. Total movement was
recorded by the Viewpoint Zebrabox for 15 minutes in 100% light. Videos were scored for
latency to seize where time to first seizure was recorded per fish.
2.6

Statistics
Data was tested for normality using the Shapiro-Wilk test and for equal variances using

the Brown-Forsythe test. All graphing and statistical analysis were conducted using Sigmaplot
14.0 software.
Analysis on larval behavior was conducted on the total distance traveled during an
acclimation phase and alternating phases of dark and light. Differences in behavior within each
line were assessed using the ANOVA on Ranks, Dunn’s posthoc, (p  0.05) because data was
non-parametric. Analysis on adult behavior was conducted on the total distance traveled,
velocity, time spent in periphery, and freezing duration. Statistical analysis for mitochondrial
bioenergetics were conducted on oxygen consumption rates for each stage. A two-way ANOVA
was performed with sex and line as factors (Student-Newman-Keuls posthoc test, p  0.05) when
appropriate for adult behavior and mitochondrial bioenergetics. Since the data was parametric,
significant differences among the three lines were assessed within each sex using a one-way
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ANOVA (Tukey’s posthoc test, p ≤ 0.05). For the seizure-induced larval exposures, seizure
latency and total distance were analyzed. Differences in treatment within each line were assessed
using the ANOVA on Ranks, Dunn’s posthoc, (p  0.05) for seizure latency data because data
was non-parametric. For total distance, a two-way ANOVA (Student-Newman-Keuls posthoc
test, p  0.05) was performed to assess treatment and line differences.
RESULTS
3.1

Roles of cnr1 and cnr2 in larval behavior
In the constitutive larval behavioral assay, unexposed larval fish from each line were

placed in a 96-well plate at 5 dpf. Each plate experienced an acclimation period from 0-10
minutes in 100% light, two dark periods (from 12-20 and 32-40 minutes) and two light periods
(from 22-30 and 42-50 minutes). The larval photomotor response and average total distance
moved per period by each line is shown in Figure 4. Generally, locomotion increased during the
dark periods, and locomotion decreased during the light periods (Figure 4A). Total distance
during the acclimation phase (Figure 4B), dark phase (Figure 4C) and light phase (Figure 4D)
was significantly increased in cnr1-/- larvae compared to 5D and cnr2-/- larvae.
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B

C

D

Figure 4: A Time course of larval photomotor response of 5D, cnr1-/-, and cnr2-/- larvae at 5
dpf. The total distance traveled (mm) per minute in the B Acclimation phase, C dark phase, and
D light phase data was plotted. Box and whisker plots were used to plot phase data where the
box represents the interquartile range (IQR) from 25-75%, the line inside the box is the median,
the whiskers represent the top and bottom 25th percentiles, and outliers are represented with
dots. For each phase, an ANOVA on Ranks followed by Dunn’s posthoc test (p  0.05, n = 4648 per line) was used for analysis, and (#) indicates significant differences between lines.
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3.2

Roles of cnr1 and cnr2 in adult behavior
In the adult behavioral assessment, the open field test was conducted using fish from each

line. The total distance traveled, velocity, time in periphery, and freezing duration was analyzed
as shown in Figure 5. There were no significant differences between total distance (Figure 5A)
or velocity (Figure 5B) among female lines. However, total distance and velocity were
significantly reduced in cnr1-/- males compared to 5D and cnr2-/- males. Time spent in the
periphery was significantly different between males and females (Figure 5C). Cnr2-/- adults
(male and female) significantly spent more time in the periphery than 5D and cnr1-/- adults.
(Figure 5C). All cnr1-/- adults had significantly different freezing durations than 5D or cnr2-/adults (Figure 5D).
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Figure 5: A velocity (cm/s), B time spent in periphery (%), and C freezing duration (s) of adult 5D,
cnr1-/- and cnr2-/- zebrafish during the open field test conducted using the Noldus EthoVision XT
video tracker. Box and whisker plots were used to plot data where the box represents the interquartile
range (IQR) from 25-75%, the line inside the box is the median, the whiskers represent the top and
bottom 25th percentiles, and outliers are represented with dots. For velocity analysis, differences
between lines were compared using one-way ANOVA followed by Tukey’s posthoc test ((#)
indicates significant difference compared to 5D and cnr2-/- (p  0.05, n = 12 adults per line per sex)).
For time in periphery and freezing duration analysis, differences between sexes and lines were
compared using two-way ANOVA followed by Student-Newman-Keuls posthoc test ((#) indicates
significant difference compared to 5D and cnr1-/-, different letters indicate significant differences
compared to 5D; (*) indicates a significant difference between sexes (p  0.05, n = 12 adults per line
per sex)).
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3.3

Roles of cnr1 and cnr2 in basal mitochondrial bioenergetics
The XF Cell Mito Stress test was used to assess mitochondrial bioenergetics by using

adult brain mitochondria from each line. Female OCR (Figure 6A) and male OCR (Figure 6B)
data was obtained from the Seahorse XFe96 analyzer. There were no significant OCR
differences among the lines in any stage of the Cell Mito Stress Test, however sex differences
were observed. There were no significant OCR differences between males and females during
the basal respiration stage (Figure 6C) or after the addition of FCCP during the maximal
respiratory capacity stage (Figure 6E). However, males had significantly higher OCR following
the addition of 1) oligomycin during the ATP-linked respiration stage (Figure 6D), and 2)
rotenone/antimycin A during the reserve capacity stage (Figure 6F).
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Figure 6: Oxygen consumption rates (pmol/min) in adult brains of 5D, cnr1-/- and cnr2-/zebrafish following the Cell Mito Stress Test conducted with the Seahorse XFe96 analyzer. A,
B show the rates as a function of time during the stages in which metabolic
activators/inhibitors were added across the respiration period in females and males,
respectively. C-F show the oxygen consumption rates prior to the addition of metabolic
activators/inhibitors (baseline, C), following the addition of oligomycin (D), FCCP (E), and
rotenone/antimycin A (F) plotted using box and whisker plots, where the box represents the
interquartile range (IQR) from 25-75%, the line inside the box is the median, the whiskers
represent the top and bottom 25th percentiles, and outliers are represented with dots. Line and
sex differences were assessed with a two-way ANOVA followed by the Student-NewmanKeuls posthoc test (#) indicates a significant difference between sexes (p  0.05, n = 3-4
brains per sex per line).
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3.4

Roles of cnr1, cnr2, THC and CBD in PTZ-induced seizures
Larval fish behavior was evaluated following a 24-hour exposure to diazepam, THC, and

CBD and subsequent seizure induction using PTZ. The time of the first seizure was recorded
from each fish to determine seizure latency, which is shown in Figure 7A. Diazepam, the
positive control, did significantly increase latency to seize in all three lines compared to PTZ.
THC and CBD exposure did not significantly increase latency to seize in any of the lines
compared to PTZ.
Total distance was also recorded following these exposures (Figure 7B). 5D larvae had
significantly different total distances compared to cnr1-/- and cnr2-/- larvae. THC and CBD
exposure did not reduce total distance in any of the lines, but diazepam reduced distance in all
lines compared to PTZ, mimicking the control group.
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Figure 7: A Latency to seize (s) and B total distance (mm) of PTZ-induced seizures in 5D, cnr1-/- and cnr2-/zebrafish following a 24-exposure from 5 to 6 dpf to 0.05% DMSO solvent control, DZP, CBD and THC. Latency
to seize data was collected by scoring 15 min videos captured using the ViewPoint Zebrabox for time to first
seizure. Total distance was measured from these videos. Box and whisker plots were used to plot data where the box
represents the interquartile range (IQR) from 25-75%, the line inside the box is the median, the whiskers represent
the top and bottom 25th percentiles, and outliers are represented with dots. Treatment groups were compared to 5
mM PTZ group using ANOVA on Ranks, followed by Dunn’s posthoc test ((#) indicates significant difference
compared to 5 mM PTZ group (p  0.05, n = 24 larvae per treatment)) for latency to seize data, and differences in
total distance traveled between treatment and line were assessed compared to the 5 mM PTZ group using a two-way
ANOVA followed by Student-Newman-Keuls posthoc test ((#) indicates significant difference compared to 5 mM
PTZ group; (*) indicates significant difference compared to cnr1-/- and cnr2-/- (p  0.05, n = 24 larvae per
treatment)).
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DISCUSSION
4.1

Adult behavioral & mitochondrial assessment
The open field test was used to determine the effect of non-functional cannabinoid

receptors on behavior in adult zebrafish. This test, when applied to animal models, allows for
observation and study of exploratory behavior and interaction with a novel environment
(Rosemberg et al., 2011). Anxious behaviors are assessed through the measurement of
thigmotaxis, which refers to the tendency of animals to stay close to walls when exploring an
open space. By applying this test to our fish, we could examine behavioral differences between
adult lines and sexes.
According to our results, non-functional cannabinoid receptors do play a role in adult
zebrafish behavior. Cnr2-/- adults spent more time in the periphery than the other two lines,
which suggests more anxious behavior. This is consistent with studies in which cnr2 knockouts
developed anxiety-like behavior under specific stressors, indicating that cnr2 expression is
necessary to reduce anxious behaviors (Ishiguro et al., 2018). The results also indicated that
among the males only, cnr1-/- adults had decreased total distances and velocities. These results
suggest significant differences between sexes that may be linked to behavioral changes.
Seizure activity has been linked to altered metabolism in a previous study using DS
animal models, but there is much to be discovered regarding metabolic changes due to loss of
functional cannabinoid receptors (Kumar et al., 2016). One relevant study demonstrated the
effects of the inhibition of cannabinoid receptor activity on liver metabolism and found that adult
mutants experience abnormal liver development and metabolism following this inhibition (Liu et
al., 2016). Another study suggested that metabolism may be indirectly altered by cannabinoid
receptor binding of THC and CBD, which may contribute to behavioral and developmental
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abnormalities (Pandelides et al., 2021). To assess constitutive changes in mitochondrial function
among 5D and mutant lines without functional cannabinoid receptor 1 or 2, the Cell Mito Stress
Test was used to create a metabolic profile of each line and each sex which shows the key stages
of mitochondrial function (Gu et al., 2021). Oxygen consumption rates (OCR) were measured
along each stage to indicate normal cellular function.
Our results indicated that there were no significant differences in OCR among lines, but
there were sex differences in mitochondrial respiration across certain complexes of the electron
transport chain. Males experienced higher OCR rates during the ATP-linked respiration stage
(after inhibiting complex V), which may be indicative of higher ATP demand, and higher OCR
after inhibiting complexes I and III, which is indicative of increased non-mitochondrial
respiration (Wang et al., 2013). These elevated rates in the adult males may contribute to the
more anxious behavior observed in the cnr2-/- adult males, but because there were no significant
differences among lines, we cannot conclude this from the mitochondrial bioenergetics
assessment. The metabolic assessment also does not explain why the adult behavioral assessment
resulted in a significant decrease in total distance and velocity in the cnr1-/- adult male fish.
However, epilepsy prevalence tends to be higher in males when compared to females (Banerjee
et al., 2009). If higher metabolic rates are indicative of higher epileptic activity and abnormal
behavior, our results are consistent with this data. Further studies are needed to investigate
behavioral and metabolic differences among sexes that could characterize the role of the ECS in
epileptic disorders.

4.2

Larval behavior and PTZ-induced activity
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The larval photomotor response assay was used to assess constitutive changes in
zebrafish swimming behavior in the 5D, cnr1-/-, and cnr2-/- lines. Following swim bladder
development (4 dpf), zebrafish larvae show a specific pattern of movement when exposed to
cycles of light and dark conditions (Burgess & Granato, 2007). The light-dark transition
increases locomotion due to an increased stress response caused by scotophobia, while the darklight transition decreases locomotion. Deviations from this pattern are typically indicative of
neural abnormalities because locomotion is dependent on brain function, nervous system
development, and visual pathways (Ali et al., 2012).
Locomotion was significantly increased across the acclimation phase, dark phase, and
light phase of the larval photomotor response assay in cnr1-/- larvae compared to 5D and cnr2-/larvae. One previous study found that cnr1-/- larvae experienced increased locomotion that was
observed during the dark phase, suggesting that this could be because of developmental changes
due to the cnr1 deficiency (Luchtenburg et al., 2019). CB1 signaling is known to mediate
neuronal and endocrine stress responses, so the absence of the cnr1 gene may contribute to an
increased stress response and result in hyperactivity (Beins et al., 2021). Cnr2-/- larvae behaved
similarly to the 5D wild-type line, indicating that the lack of cnr2 has no significant effects on
locomotion in the larval photomotor response assay.
THC and CBD exposures were proposed due to their previous reduction of PTZ-induced
seizure activity in zebrafish larvae in a previous study (Thornton et al., 2020), in which total
distance was significantly reduced by THC (1 and 4 M) and CBD (0.6 and 1 M) in wild-type
models and DS fish (scn1Lab-/-). In the present study, neither total distance traveled nor latency
to seize were significantly altered by cannabinoid treatments compared to PTZ. However, total
distance traveled was significantly reduced in the 5D wild-type model compared to the other
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lines. The knockout models were more hyperactive overall, which matched the increased
locomotion observed in cnr1-/- larvae during the constitutive photomotor response assay.
Following exposure, cnr2-/- larvae were also more hyperactive across all treatment groups
compared to the 5D, deviating from the behavior observed in the constitutive assay.
THC is a known agonist of CB1 and CB2, with THC having a higher binding affinity for
the CB1 receptor. Our results indicated that THC, compared to the PTZ group, had no significant
effects on latency to seize or total distance in any of the lines. In a previous study, wild-type
larvae that were pre-exposed to THC and CBD and induced using 2.5 and 5 mM PTZ
experienced a reduction in total activity (Samarut et al., 2019). If THC is a CB1 agonist, these
results suggest that the effects of THC are cnr1- and cnr2-mediated. However, although total
distance was reduced in the 5D larvae compared to the knockout lines, we could not conclude
whether the cnr1 and cnr2 genes were necessary for THC to be able to elicit a response due to
the lack of significant differences between treatments in each line.
A similar conclusion for CBD, an allosteric modulator of the cannabinoid receptors, was
reached. Our results indicated that CBD had no significant effects on latency to seize or total
distance compared to the PTZ group in any of the lines. Although CBD has been proposed as a
viable anticonvulsant therapy, perhaps more research is needed to determine the role of CBD in
the ECS, especially because there are studies which indicate that CBD may have different modes
of action that are independent from cnr1 and cnr2 (Pertwee, 2008).
4.3

Conclusion
In order to characterize the effects of non-functional cannabinoid receptors in larval and

adult zebrafish models, we investigated whether the absence of cannabinoid receptor 1 or 2
would result in changes in behavior, metabolism, and/or seizure-induced activity. In summary,
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we identified significant differences in behavior and metabolism in cnr1 and cnr2 knockout adult
fish models that were consistent with previous studies. This study also found significant
differences among sexes that may play a role in behavior and metabolism of adult fish. However,
we were not able to determine the specific roles that cannabinoid receptor 1 and 2 may play in
seizure-induced activity. Our data demonstrated that exposure to THC and CBD had no
significant effects in any of the lines, which may suggest that these cannabinoids may have
different modes of action. In this study, THC and CBD were not effective in reducing PTZ
seizure-induced activity.
We hope that this research will inform further studies on the roles of cannabinoid
receptors in other epilepsy models in order to determine the best antiepileptic drug treatments.
An important research question raised is why are the adverse behavioral effects observed in cnrnull animals as adults but not observed in the larval stages? Delving into further research on
larval behavior and metabolism in fish models should provide clarity and lead to a better
understanding of the role of the ECS in epilepsy.
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